JAMA Surg: Circulating exomer lncRNA-GC1 for early gastric cancer diagnosis

Gastric cancer(GC)-related long non-coding RNA1 (lncRNA-GC1) plays an important role in the development of stomach cancer, and researchers recently explored thevalue of cyclosisl exosome lncRNA-GC1 for early detection of GCdiagnosisresearchers conducted a multi-phase study of cyclic exosome lncRNA-GC1 to detect GC at an early stage, including GC patients (n?522), gastric precancerous patients (n s.85) and healthy volunteers (HDs; n?219)The diagnostic efficiency of lncRNA-GC1 and 3 traditional biomarkers (cancer embryo antigens (CEA), cancer antigen 72-4 (CA72-4) and CA19-9 was calculated by reverse transcriptus-polymerase chain reaction, and diagnostic efficiency was evaluated according to the area (AUC), specificity and sensitivity of the curveof the 826 participants in the, 508 were male (61.5 per cent), with a median age of 60During the pilot phase, lncRNA-GC1 has better diagnostic performance than standard biomarkers CEA, CA72-4, and CA19-9 (AUC-0.9033) and can be used to identify PATIENTs with GC and HDsIn addition, the level of lncRNA-GC1 in GC cell culture fluid was significantly higher than that of normal gastric epithelial cellsLncRNA-GC is highly efficient in identifying GC patients, precancerous patients, and HDs, and lncRNA-GC1 shows higher AUC in early detection of GC, especially in patients with standard biomarker-negative GC patientsIn addition, the level of cyclic exosome lncRNA-GC1 varies significantly from early to late GC and is independent of pathological classification and Lauren classificationIn addition, the circulating lncRNA-GC1 level remains the same after treatment by RNase and remains constant after prolonged exposure to room temperature or repeated freezing and thawingTotal circulation lncRNA-GC1 is almost entirely packaged in the outer body, not in the free form in the plasmastudies have shown that cyclic exomer lncRNA-GC1 can be used as an uninvasive biomarker to detect early gastric cancer and monitor disease progression, combining the circulating exosome lncRNA-GC1 test with endoscopy to improve the early diagnosis rate of stomach cancer